Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Metformin increases bone marrow adipose tissue by promoting mesenchymal stromal cells apoptosis.

Duan W., Zou H., Zang N., Ma D., Yang B., Zhu L.

Animal Study on Type 2 Diabetes, published in Aging (Albany NY) (2023) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Aging (Albany NY) (2023)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
36645914
DOI
10.18632/aging.204486

Abstract (original English)

Bone marrow adipose tissue (MAT) has the potential to exert both local and systemic effects on metabolic homeostasis. As a first-line drug used to treat type 2 diabetes mellitus, metformin has conflicting effects on MAT and bone marrow mesenchymal stem cell (BM-MSC) differentiation. Through a series of experiments in vivo and in vitro , we found that except improving the glucose and lipid metabolism disorder in ob / ob mice, 200 mg/kg metformin increased MAT in mice tibia, and prompted osteogenic genes ( RunX2, OPN, OCN ) and lipogenic genes ( Ppar-γ, Cebpα, Scd1 ) expression in mice bone marrow. However, metformin promoted osteogenesis and inhibited lipogenesis of MSC in vitro , which is inconsistent with the results in vivo . Given MAT being considered the "filler" of the space after the apoptosis of bone marrow stroma, the effect of metformin on MSC apoptosis was examined. We discovered that metformin induces MSC apoptosis in vivo and in vitro . Therefore, we speculated that the increased MAT in mice tibia may be attributed to the filling of adipose tissue after apoptosis of bone marrow stromal cells induced by metformin. The increased MAT may be involved in the regulation of metformin on glucose, lipid, and bone metabolism in diabetic mice, providing a new way to understand the metabolic regulation of metformin. While increased MAT-associated insulin resistance and metaboli

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
MiceAnimalsBone MarrowDiabetes Mellitus, ExperimentalMetforminDiabetes Mellitus, Type 2Adipose TissueMesenchymal Stem CellsOsteogenesisCell Differentiation

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research